Albireo Pharma, Inc. (ALBO) financial statements (2020 and earlier)

Company profile

Business Address 10 POST OFFICE SQUARE
BOSTON, MA 02109
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
9/30/2016
9/30/2015
9/30/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1321645330294125
Cash and cash equivalents1321645330294125
Receivables 310  0
Other undisclosed current assets10111000
Total current assets:1421685531294125
Noncurrent Assets
Property, plant and equipment1000 00
Intangible assets, net (including goodwill)17171718000
Goodwill17171718   
Intangible assets, net (excluding goodwill)   0000
Other noncurrent assets5011   
Total noncurrent assets:23181819001
TOTAL ASSETS:1651857350294125
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities181379121
Accounts payable5411000
Accrued liabilities13868000
Employee-related liabilities    011
Debt   3   
Derivative instruments and hedges, liabilities   1   
Restructuring reserve    1  
Other liabilities1000   
Other undisclosed current liabilities   0000
Total current liabilities:1913813222
Noncurrent Liabilities
Long-term debt and lease obligation4      
Operating lease, liability4
Liabilities, other than long-term debt, including:400 00 
Other liabilities4 0 00 
Other undisclosed liabilities, other than long-term debt 0     
Other undisclosed noncurrent liabilities4550  001
Total noncurrent liabilities:53500 001
Total liabilities:7263813223
Stockholders' equity
Stockholders' equity attributable to parent, including:931236537264023
Preferred stock     0 
Common stock000001 
Additional paid in capital24621511561288287252
Accumulated other comprehensive income6411   
Accumulated deficit(159)(96)(50)(26)(262)(248) 
Other undisclosed stockholders' equity attributable to parent      (229)
Total stockholders' equity:931236537264023
TOTAL LIABILITIES AND EQUITY:1651857350294125

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
9/30/2016
9/30/2015
9/30/2014
Revenue, net011  1
Gross profit:1013011  1
Operating expenses(71)(51)(25)(24)(14)(20)(19)
Operating loss:(61)(38)(25)(12)(14)(20)(19)
Nonoperating income (expense)4(3)0(3)   
Foreign currency transaction loss, before tax(4)(5)     
Loss from continuing operations before equity method investments, income taxes:(57)(41)(24)(15)(14)(20)(19)
Other undisclosed income (loss) from continuing operations before income taxes(5)(5)0(1)015
Loss from continuing operations before income taxes:(63)(46)(24)(16)(14)(19)(14)
Income tax expense (0)(0)(0)(0)(0)(0)
Net loss available to common stockholders, diluted:(63)(46)(24)(16)(14)(19)(14)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
9/30/2016
9/30/2015
9/30/2014
Net loss:(63)(46)(24)(16)(14)(19)(14)
Other comprehensive income (loss)23(0)1   
Comprehensive loss, net of tax, attributable to parent:(61)(43)(25)(16)(14)(19)(14)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: